INTRODUCTION
The importance of laboratory predictors of the severity of common diseases has been growing along with the increasing availability of early therapeutic approaches to prevent or minimize disease-related complications. Therefore, the incidence and severity of atherothrombotic complications could be significantly reduced if the patients at higher risk for these complications are properly anticipated. However, one of the foremost current challenges is identifying patients with a higher risk of a poor outcome before the appearance of complications. Having these patients identified would cause a major impact not only on the quality of life of individual subjects but also on the pharmacoeconomy of entire communities, since the allocation of resources would be more rational.
Many laboratory markers have been investigated to determine if they are predictive of an increased risk of atherosclerosis progression and the emergence of its complications. With regard to peripheral arterial disease (PAD), thrombomodulin blood levels, for example, were not significantly elevated in patients with critical limb ischemia in comparison to patients with intermittent claudication. Thus, thrombomodulin is not a good predictor of PAD worsening. 1 Among the clinical and laboratory markers available, the ankle-brachial pressure index (ABPI) is a well-known predictor of PAD worsening. 2 A low ABPI was associated with an increased risk of cardiovascular events, including death, independent of metabolic syndrome and other major cardiovascular disease risk factors. 3 Furthermore, Fowkes et al. recently demonstrated that ABPI determination may improve the accuracy of cardiovascular risk prediction beyond the one achieved when using the Framingham risk score. 4 The value of oxidized low-density lipoprotein (oxLDL) as a predictor of atherothrombotic complications has also been investigated. OxLDL was associated with carotid intimal-media thickness, unstable plaques in the coronary and carotid arteries, impaired brachial and coronary endothelial function, and coronary artery disease.
Moreover, oxLDL was also associated with the presence, extent,and interim development of carotid and femoral atherosclerosis over a five-year period.
However, only limited data are available regarding a potential relationship between ABPI and plasma oxLDL levels in subjects with PAD.
Because ABPI is primarily a severity index of the peripheral arteries' disease, we hypothesized that patients with lower ABPI would have higher plasma oxLDL levels than patients with higher ABPI.
The aim of the present study was to investigate such a correlation in patients with PAD.
METHODS

Population
Eighty-five consecutive patients with PAD from the Vascular Surgery Division of the Hospital das Clinicas of the University of São Paulo were included in this study. The inclusion criteria were an ABPI < 0.90 and the presence of either intermittent claudication or critical lower leg ischemia. Informed consent from all subjects was obtained before this trial.
Autoantibody plasma level evaluation
A blood sample was drawn from a vein in the arm of each subject after an eight-hour overnight fast. The plasma was isolated and stored for subsequent analysis after centrifugation at 2500 rpm and 4°C for 20 minutes.
The plasma level of IgG autoantibodies against oxLDL (from this point on mentioned just as oxLDL levels) was evaluated as previously described. 5 In brief, an enzymelinked immunosorbent assay was used. The optical density of the samples was read in a photometric plate reader at 460 nm. Each plate was calibrated against an internal control (total IgG with protein concentration of 0.116 µg/mL in phosphate-buffered saline [PBS]; pH 7.4; 0.05 M) and a blank PBS sample. Thus, the results for oxLDL levels are shown according to the following formula: (anti-oxLDL antibody -blank)/internal control.
Statistical analysis
The oxLDL levels were categorized into quartiles according to ABPI, and the Kruskal-Wallis test was used to investigate whether there was a significant difference among quartiles. The level of significance was set to 0.05. Table 1 shows the demographic data of the sample population from this study. It shows the predominance of smoking and hypertension as risk factors for PAD, and also the higher incidence of the disease in males. The ABPI`s interquartile range is quite wide, depicting this sample is highly representative of the population of patients with PAD. Table 2 depicts the median oxLDL levels per ABPI quartile. There seems to be no substantial variation in oxLDL levels among the different ABPI quartiles.
RESULTS
The statistical analysis revealed that there is no significant difference in oxLDL level among the ABPI-based quartiles for this population (p = 0.33).
DISCUSSION
Profiling patients for risk factors regarding peripheral arterial disease is a continuously ongoing process. [6] [7] [8] [9] [10] Among the many studied markers of PAD worsening, oxLDL is earning increasing importance as evidence of its participation in atherogenesis has accumulated. The development of atherosclerosis depends on a delicate balance between proinflammatory stimuli and antiinflammatory, anti-oxidative defense mechanisms.
A typical feature of atherosclerosis is the accumulation of oxidatively modified low-density lipoproteins within plaques, and these lipoproteins are hypothesized to contribute to the inflammatory state of atherosclerosis and to play a key role in its pathogenesis.
As low-density lipoproteins (LDL) traverses the subendothelial space, it becomes oxidized and may induce endothelial dysfunction, one of the earliest manifestations of atherosclerosis. Indeed, oxLDL levels correlate with the occurrence of endothelial dysfunction. Endothelial dysfunction improves following lipid-lowering therapy with apheresis or statins. 11 Native, non-oxidized lipoproteins elicit no or only weak effects on the production of reactive oxygen species. On the other hand, oxidation of LDL increases its capacity to stimulate O 2 -formation, either through activating the lectin-like receptor LOX-1 12 or increasing the production and concentration of asymmetric dimethyl L-arginine. 13 The latter is an endogenous inhibitor of nitric oxide synthase and increases oxidative stress. 14 
OxLDL-induced O 2
-accumulates at the site of inflammation within atherosclerotic plaques, in the direct vicinity of all cell types that are involved in the pathogenesis of the disease. Experimental data showed that this accumulation may lead to cell proliferation, hypertrophy, apoptosis,or necrosis, depending on the amount and duration of the exposure of the cells to oxLDL. 15, 16 Moreover, this accumulation may also inactivate nitric oxide 17 and sensitize the contractile apparatus of the vessel wall, thus inducing vasoconstriction. 18 OxLDL is not present in normal arteries. However, it is present in many types of lesions, including very early fetal aortic lesions that form in response to maternal hypercholesterolemia during gestation. OxLDL is present even before monocytes enter into the vessel wall, suggesting that LDL oxidation occurs a priori in atherogenesis. 19 Unstable plaques in human carotid and coronary arteries are significantly enriched for oxLDL. Carotid plaques that were removed with endarterectomy and considered vulnerable and unstable plaques after pathology studies presented a much greater content of oxLDL than stable carotid plaques. 20 Furthermore, another study showed that such content was significantly decreased after treatment with statins. 21 In addition, oxLDL plasma levels correlate with the incidence of angiographically complex coronary plaques. 22 The role of oxLDL as a marker or predictor of atherosclerotic involvement or atherothrombotic complications has already been assessed through some interesting studies. These studies show correlations of oxLDL plasma levels with morphologic and functional abnormalities, as well as with clinical outcomes.
In subjects with familial hyperlipidemia, elevated blood oxLDL and LDL-cholesterol levels were associated with increased carotid intimal-media thickness. 23 In two other studies, elevated plasma oxLDL levels were associated with increased carotid intimal-media thickness in asymptomatic subjects whose relatives had familial hypercholesterolemia and also in asymptomatic middle-aged males. 24, 25 A strong correlation between endothelial function abnormalities and high plasma levels of oxLDL was also demonstrated with regard to the coronary and brachial arteries. 26, 27 OxLDL plasma levels were also independent predictors of coronary artery disease 28 and were even stronger predictors than LDL and total cholesterol blood levels. 29 Finally, a prospective case-control study in men showed that oxLDL plasma levels were higher in the patients who would later present cardiovascular events compared to those who sustained no such events in the future. 30 Our results showed no correlation between the ABPI and oxLDL levels in subjects with clinically evident PAD with a wide range of clinical manifestations. This finding differs from the results of some other investigations.
A study involving apparently healthy, atherosclerosisfree individuals, with ages ranging from 35 to 55 years, found an association between high oxLDL blood levels and the presence of plaques, or at least intimal thickening, in the femoral arteries. 31 Another trial demonstrated that the oxidized phospholipids/apolipoprotein B ratio was strongly and significantly associated with the presence, extent and development of carotid and femoral atherosclerosis and predicted the presence of symptomatic cardiovascular disease. 32 Taken together, these two studies show that elevated plasma oxLDL levels may either appear before the disease becomes clinically evident or be strong predictors of the worsening of the disease in the future.
Another key aspect when assessing the relevance oxLDL levels as a severity predictor is its timing.
In this way, it was already observed that long-standing type 2 diabetic patients show a significant inverse correlation between the ABPI and plasma oxLDL levels; this correlation is not observed in recently diagnosed type 2 diabetic subjects. 33 It is important to stress that the long-standing diabetic group mentioned above presented an ABPI of 0.86 ± 0.29 (mean ± standard deviation), which is significantly higher than the ABPI found in our population. The finding of a higher ABPI is a sign that some individuals of that group had no or very early atherosclerotic compromise, in sharp contrast with a substantial lower median ABPI found in our population.
In our study, all the patients were in an advanced stage of PAD. Nonetheless, a wide range of clinical severities was observed within that population. Therefore, plasma oxLDL levels were assessed in patients with diverse degrees of severity. Even the patients with higher ABPI values presented a long-standing, clinically evident disease.
These results could indicate that plasma oxLDL levels may have a stronger impact in the early phase of the disease but not in the late phase, when PAD is already established.
Indeed, the work from Piarulli et al. demonstrated that plasma oxLDL levels were increased just among the longstanding diabetes patients. Their finding may be because steady and prolonged metabolic abnormalities are required to furnish a favorable environment for LDL to be oxidized. The pathophysiologic processes that occur due to the presence of oxLDL in the arterial wall microenvironment take place long thereafter. By the time the atherosclerotic disease becomes evident, the role played by oxLDL may be much less important.
There is also evidence that plasma oxLDL levels is increased in acute coronary syndrome 34 and that these increased levels may have a relationship with the severity and the timing of that ischemic event. Plasma oxLDL levels are higher in the acute phase of the myocardial ischemia and decrease gradually over time. In our population, no patient presented acute ischemia or sudden worsening of the underlying critical ischemia. It is possible that in such stable cases, with no plaque-related acute events, great changes in oxLDL levels are not present.
A limitation of our work is its cross-sectional design. Although this kind of approach may enable important inferences, a prospective longitudinal study may reach more robust conclusions. However, to our knowledge, this is the first study assessing the correlation between ABPI and plasma oxLDL levels in patients with clinically evident PAD, and thus this study provides insight into the importance of this marker.
CONCLUSION
In conclusion, there is no correlation between ABPI and the plasma levels of autoantibodies against oxLDL in patients with clinically evident PAD. OxLDL is not a good predictor of the worsening or severity of peripheral atherosclerosis.
